{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:02:27Z","timestamp":1791590547023,"version":"4.3.4"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["MSIT 800-20240195"],"award-info":[{"award-number":["MSIT 800-20240195"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022M3A9D3016848"],"award-info":[{"award-number":["2022M3A9D3016848"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00356421"],"award-info":[{"award-number":["RS-2024-00356421"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-000279801"],"award-info":[{"award-number":["RS-2023-000279801"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-60445-6","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:15:39Z","timestamp":1751368539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Type 1 interferon signature and allograft inflammatory factor-1 contribute to refractoriness to TNF inhibition in ankylosing spondylitis"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6217-5022","authenticated-orcid":false,"given":"Woogil","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1575-9007","authenticated-orcid":false,"given":"Eunyoung Emily","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9612-0020","authenticated-orcid":false,"given":"Seongwan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baekgyu","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Gang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo Yoon","family":"Ban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Rim","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seon Uk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7240-3744","authenticated-orcid":false,"given":"Jong-Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6308-9503","authenticated-orcid":false,"given":"Eui-Cheol","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5885-2754","authenticated-orcid":false,"given":"Inkyung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8261-7044","authenticated-orcid":false,"given":"Jeong Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6975-8627","authenticated-orcid":false,"given":"Eun Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Single-Cell Atlas of Immune Diseases Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"60445_CR1","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit, M. et al. The development of assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann. Rheum. Dis. 68, 777\u2013783 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"60445_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit, M. et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann. Rheum. Dis. 70, 25\u201331 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"60445_CR3","doi-asserted-by":"publisher","first-page":"15013","DOI":"10.1038\/nrdp.2015.13","volume":"1","author":"J Sieper","year":"2015","unstructured":"Sieper, J. et al. Axial spondyloarthritis. Nat. Rev. Dis. Prim. 1, 15013 (2015).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"60445_CR4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/art.39458","volume":"68","author":"AS Kehl","year":"2016","unstructured":"Kehl, A. S., Corr, M. & Weisman, M. H. Review: Enthesitis: New Insights Into Pathogenesis, Diagnostic Modalities, and Treatment. Arthritis Rheumatol. 68, 312\u2013322 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"60445_CR5","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","volume":"374","author":"JD Taurog","year":"2016","unstructured":"Taurog, J. D., Chhabra, A. & Colbert, R. A. Ankylosing Spondylitis and Axial Spondyloarthritis. N. Engl. J. Med 374, 2563\u20132574 (2016).","journal-title":"N. Engl. J. Med"},{"key":"60445_CR6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun, J. et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359, 1187\u20131193 (2002).","journal-title":"Lancet"},{"key":"60445_CR7","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJMoa012664","volume":"346","author":"JD Gorman","year":"2002","unstructured":"Gorman, J. D., Sack, K. E. & Davis, J. C. Jr Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N. Engl. J. Med 346, 1349\u20131356 (2002).","journal-title":"N. Engl. J. Med"},{"key":"60445_CR8","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"N Haroon","year":"2013","unstructured":"Haroon, N. et al. The impact of tumor necrosis factor \u03b1 inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 65, 2645\u20132654 (2013).","journal-title":"Arthritis Rheum."},{"key":"60445_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K","volume":"44","author":"M Dougados","year":"2001","unstructured":"Dougados, M. et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum. 44, 180\u2013185 (2001).","journal-title":"Arthritis Rheum."},{"key":"60445_CR10","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/ncprheum0297","volume":"2","author":"A Boonen","year":"2006","unstructured":"Boonen, A. A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis. Nat. Clin. Pr. Rheumatol. 2, 546\u2013553 (2006).","journal-title":"Nat. Clin. Pr. Rheumatol."},{"key":"60445_CR11","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/ncprheum0336","volume":"2","author":"KL Winthrop","year":"2006","unstructured":"Winthrop, K. L. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat. Clin. Pr. Rheumatol. 2, 602\u2013610 (2006).","journal-title":"Nat. Clin. Pr. Rheumatol."},{"key":"60445_CR12","doi-asserted-by":"publisher","first-page":"1079851","DOI":"10.1155\/2016\/1079851","volume":"2016","author":"JM Gane","year":"2016","unstructured":"Gane, J. M., Stockley, R. A. & Sapey, E. TNF-\u03b1 Autocrine Feedback Loops in Human Monocytes: the pro- and anti-inflammatory roles of the tnf-\u03b1 receptors support the concept of selective TNFR1 blockade in vivo. J. Immunol. Res 2016, 1079851 (2016).","journal-title":"J. Immunol. Res"},{"key":"60445_CR13","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.4049\/jimmunol.179.3.1449","volume":"179","author":"S Iwamoto","year":"2007","unstructured":"Iwamoto, S. et al. TNF-alpha drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses. J. Immunol. 179, 1449\u20131457 (2007).","journal-title":"J. Immunol."},{"key":"60445_CR14","doi-asserted-by":"publisher","first-page":"9570129","DOI":"10.1155\/2017\/9570129","volume":"2017","author":"R Huber","year":"2017","unstructured":"Huber, R. et al. TNF tolerance in monocytes and macrophages: characteristics and molecular mechanisms. J. Immunol. Res 2017, 9570129 (2017).","journal-title":"J. Immunol. Res"},{"key":"60445_CR15","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/ni.3818","volume":"18","author":"SH Park","year":"2017","unstructured":"Park, S. H. et al. Type I interferons and the cytokine TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation. Nat. Immunol. 18, 1104\u20131116 (2017).","journal-title":"Nat. Immunol."},{"key":"60445_CR16","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten, D. et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N. Engl. J. Med 373, 2534\u20132548 (2015).","journal-title":"N. Engl. J. Med"},{"key":"60445_CR17","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/art.40070","volume":"69","author":"FJ Blanco","year":"2017","unstructured":"Blanco, F. J. et al. Secukinumab in active rheumatoid arthritis: a phase iii randomized, double-blind, active comparator- and placebo-controlled study. Arthritis Rheumatol. 69, 1144\u20131153 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"60445_CR18","doi-asserted-by":"publisher","first-page":"385352","DOI":"10.1155\/2014\/385352","volume":"2014","author":"Y Zheng","year":"2014","unstructured":"Zheng, Y. et al. TNF\u03b1 promotes Th17 cell differentiation through IL-6 and IL-1\u03b2 produced by monocytes in rheumatoid arthritis. J. Immunol. Res 2014, 385352 (2014).","journal-title":"J. Immunol. Res"},{"key":"60445_CR19","doi-asserted-by":"publisher","first-page":"7559","DOI":"10.18632\/oncotarget.13791","volume":"8","author":"YC Lin","year":"2017","unstructured":"Lin, Y. C. et al. The immunomodulatory effects of TNF-\u03b1 inhibitors on human Th17 cells via ROR\u03b3t histone acetylation. Oncotarget 8, 7559\u20137571 (2017).","journal-title":"Oncotarget"},{"key":"60445_CR20","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.jaci.2018.05.015","volume":"142","author":"JM Bae","year":"2018","unstructured":"Bae, J. M. et al. Paradoxical psoriasis following anti-TNF therapy in ankylosing spondylitis: A population-based cohort study. J. Allergy Clin. Immunol. 142, 1001\u20131003.e2 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"60445_CR21","doi-asserted-by":"publisher","first-page":"R126","DOI":"10.1186\/ar3431","volume":"13","author":"DY Chen","year":"2011","unstructured":"Chen, D. Y. et al. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-\u03b1 therapy. Arthritis Res Ther. 13, R126 (2011).","journal-title":"Arthritis Res Ther."},{"key":"60445_CR22","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1136\/annrheumdis-2011-201024","volume":"71","author":"S Alzabin","year":"2012","unstructured":"Alzabin, S. et al. Incomplete response of inflammatory arthritis to TNF\u03b1 blockade is associated with the Th17 pathway. Ann. Rheum. Dis. 71, 1741\u20131748 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"60445_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/ard.2008.102277","volume":"69","author":"N Haroon","year":"2010","unstructured":"Haroon, N. et al. From gene expression to serum proteins: biomarker discovery in ankylosing spondylitis. Ann. Rheum. Dis. 69, 297\u2013300 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"60445_CR24","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/art.24838","volume":"61","author":"MK de Vries","year":"2009","unstructured":"de Vries, M. K. et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum. 61, 1484\u20131490 (2009).","journal-title":"Arthritis Rheum."},{"key":"60445_CR25","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3899\/jrheum.141278","volume":"42","author":"X Baraliakos","year":"2015","unstructured":"Baraliakos, X. et al. Predictors of clinical remission under anti-tumor necrosis factor treatment in patients with ankylosing spondylitis: pooled analysis from large randomized clinical trials. J. Rheumatol. 42, 1418\u20131426 (2015).","journal-title":"J. Rheumatol."},{"key":"60445_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13075-023-03044-4","volume":"25","author":"M Hwang","year":"2023","unstructured":"Hwang, M. et al. Quantitative proteomic screening uncovers candidate diagnostic and monitoring serum biomarkers of ankylosing spondylitis. Arthritis Res. Ther. 25, 57 (2023).","journal-title":"Arthritis Res. Ther."},{"key":"60445_CR27","doi-asserted-by":"publisher","first-page":"e222312","DOI":"10.1001\/jamanetworkopen.2022.2312","volume":"5","author":"R Wang","year":"2022","unstructured":"Wang, R., Dasgupta, A. & Ward, M. M. Predicting probability of response to tumor necrosis factor inhibitors for individual patients with ankylosing spondylitis. JAMA Netw. Open 5, e222312 (2022).","journal-title":"JAMA Netw. Open"},{"key":"60445_CR28","doi-asserted-by":"publisher","first-page":"e000079","DOI":"10.1136\/rmdopen-2015-000079","volume":"2","author":"D Aeberli","year":"2016","unstructured":"Aeberli, D. et al. Regulation of peripheral classical and non-classical monocytes on infliximab treatment in patients with rheumatoid arthritis and ankylosing spondylitis. RMD Open 2, e000079 (2016).","journal-title":"RMD Open"},{"key":"60445_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41587-021-01033-z","volume":"40","author":"E Dann","year":"2022","unstructured":"Dann, E. et al. Differential abundance testing on single-cell data using k-nearest neighbor graphs. Nat. Biotechnol. 40, 245\u2013253 (2022).","journal-title":"Nat. Biotechnol."},{"key":"60445_CR30","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41590-020-0661-1","volume":"21","author":"A Giladi","year":"2020","unstructured":"Giladi, A. et al. Cxcl10+ monocytes define a pathogenic subset in the central nervous system during autoimmune neuroinflammation. Nat. Immunol. 21, 525\u2013534 (2020).","journal-title":"Nat. Immunol."},{"key":"60445_CR31","doi-asserted-by":"publisher","first-page":"eabf2846","DOI":"10.1126\/sciimmunol.abf2846","volume":"7","author":"DP Simmons","year":"2022","unstructured":"Simmons, D. P. et al. SLAMF7 engagement superactivates macrophages in acute and chronic inflammation. Sci. Immunol. 7, eabf2846 (2022).","journal-title":"Sci. Immunol."},{"key":"60445_CR32","doi-asserted-by":"publisher","first-page":"eaaz8836","DOI":"10.1126\/sciadv.aaz8836","volume":"7","author":"M Trizzino","year":"2021","unstructured":"Trizzino, M. et al. EGR1 is a gatekeeper of inflammatory enhancers in human macrophages. Sci. Adv. 7, eaaz8836 (2021).","journal-title":"Sci. Adv."},{"key":"60445_CR33","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41586-023-06816-9","volume":"625","author":"A Cui","year":"2024","unstructured":"Cui, A. et al. Dictionary of immune responses to cytokines at single-cell resolution. Nature 625, 377\u2013384 (2024).","journal-title":"Nature"},{"key":"60445_CR34","doi-asserted-by":"publisher","first-page":"iyad031","DOI":"10.1093\/genetics\/iyad031","volume":"224","author":"TGO Consortium","year":"2023","unstructured":"Consortium, T. G. O. et al. The gene ontology knowledgebase in 2023. Genetics 224, iyad031 (2023).","journal-title":"Genetics"},{"key":"60445_CR35","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3389\/fimmu.2018.01135","volume":"9","author":"A Michalska","year":"2018","unstructured":"Michalska, A. et al. A positive feedback amplifier circuit that regulates interferon (IFN)-stimulated gene expression and controls type i and type ii ifn responses. Front Immunol. 9, 1135 (2018).","journal-title":"Front Immunol."},{"key":"60445_CR36","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1038\/emboj.2013.203","volume":"32","author":"H Cheon","year":"2013","unstructured":"Cheon, H. et al. IFN\u03b2-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. Embo j. 32, 2751\u20132763 (2013).","journal-title":"Embo j."},{"key":"60445_CR37","doi-asserted-by":"publisher","first-page":"baw100","DOI":"10.1093\/database\/baw100","volume":"2016","author":"AD Rouillard","year":"2016","unstructured":"Rouillard, A. D. et al. The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. Database 2016, baw100 (2016).","journal-title":"Database"},{"key":"60445_CR38","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten, D. et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382, 1705\u20131713 (2013).","journal-title":"Lancet"},{"key":"60445_CR39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.humimm.2015.11.008","volume":"77","author":"A Pawlik","year":"2016","unstructured":"Pawlik, A. et al. Expression of allograft inflammatory factor-1 in peripheral blood monocytes and synovial membranes in patients with rheumatoid arthritis. Hum. Immunol. 77, 131\u2013136 (2016).","journal-title":"Hum. Immunol."},{"key":"60445_CR40","doi-asserted-by":"publisher","first-page":"e136092","DOI":"10.1172\/jci.insight.136092","volume":"5","author":"DM Elizondo","year":"2020","unstructured":"Elizondo, D. M. et al. Allograft inflammatory factor-1 in myeloid cells drives autoimmunity in type 1 diabetes. JCI Insight 5, e136092 (2020).","journal-title":"JCI Insight"},{"key":"60445_CR41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13075-016-0930-4","volume":"18","author":"W Park","year":"2016","unstructured":"Park, W. et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 18, 25 (2016).","journal-title":"Arthritis Res Ther."},{"key":"60445_CR42","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nm.3895","volume":"21","author":"MWL Teng","year":"2015","unstructured":"Teng, M. W. L. et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat. Med. 21, 719\u2013729 (2015).","journal-title":"Nat. Med."},{"key":"60445_CR43","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni.2416","volume":"13","author":"Y Lee","year":"2012","unstructured":"Lee, Y. et al. Induction and molecular signature of pathogenic TH17 cells. Nat. Immunol. 13, 991\u2013999 (2012).","journal-title":"Nat. Immunol."},{"key":"60445_CR44","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1016\/j.cell.2021.11.018","volume":"184","author":"A Schnell","year":"2021","unstructured":"Schnell, A. et al. Stem-like intestinal Th17 cells give rise to pathogenic effector T cells during autoimmunity. Cell 184, 6281\u20136298.e23 (2021).","journal-title":"Cell"},{"key":"60445_CR45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41590-022-01387-9","volume":"24","author":"A Schnell","year":"2023","unstructured":"Schnell, A., Littman, D. R. & Kuchroo, V. K. TH17 cell heterogeneity and its role in tissue inflammation. Nat. Immunol. 24, 19\u201329 (2023).","journal-title":"Nat. Immunol."},{"key":"60445_CR46","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.immuni.2012.10.018","volume":"38","author":"E Segura","year":"2013","unstructured":"Segura, E. et al. Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity 38, 336\u2013348 (2013).","journal-title":"Immunity"},{"key":"60445_CR47","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.3892\/mmr.2017.6992","volume":"16","author":"H Sha","year":"2017","unstructured":"Sha, H. et al. ATF3 promotes migration and M1\/M2 polarization of macrophages by activating tenascin\u2011C via Wnt\/\u03b2\u2011catenin pathway. Mol. Med Rep. 16, 3641\u20133647 (2017).","journal-title":"Mol. Med Rep."},{"key":"60445_CR48","doi-asserted-by":"publisher","first-page":"4446","DOI":"10.4049\/jimmunol.1500204","volume":"195","author":"LI Labzin","year":"2015","unstructured":"Labzin, L. I. et al. ATF3 is a key regulator of macrophage IFN responses. J. Immunol. 195, 4446\u20134455 (2015).","journal-title":"J. Immunol."},{"key":"60445_CR49","doi-asserted-by":"publisher","first-page":"102036","DOI":"10.1016\/j.jbc.2022.102036","volume":"298","author":"X Han","year":"2022","unstructured":"Han, X. et al. SGK1 negatively regulates inflammatory immune responses and protects against alveolar bone loss through modulation of TRAF3 activity. J. Biol. Chem. 298, 102036 (2022).","journal-title":"J. Biol. Chem."},{"key":"60445_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24609-4","volume":"12","author":"T Ban","year":"2021","unstructured":"Ban, T. et al. Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease. Nat. Commun. 12, 4379 (2021).","journal-title":"Nat. Commun."},{"key":"60445_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02915-1","volume":"19","author":"L Zheng","year":"2021","unstructured":"Zheng, L. et al. ELK4 promotes the development of gastric cancer by inducing M2 polarization of macrophages through regulation of the KDM5A-PJA2-KSR1 axis. J. Transl. Med 19, 342 (2021).","journal-title":"J. Transl. Med"},{"key":"60445_CR52","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1182\/blood-2019-124839","volume":"134","author":"L Rui","year":"2019","unstructured":"Rui, L. Oncogenic Cooperation between EGR1 and BRD4 in Diffuse Large B Cell Lymphoma. Blood 134, 1508\u20131508 (2019).","journal-title":"Blood"},{"key":"60445_CR53","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/ni.1990","volume":"12","author":"T Krausgruber","year":"2011","unstructured":"Krausgruber, T. et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 12, 231\u2013238 (2011).","journal-title":"Nat. Immunol."},{"key":"60445_CR54","doi-asserted-by":"publisher","first-page":"780436","DOI":"10.1155\/2012\/780436","volume":"2012","author":"CM Cham","year":"2012","unstructured":"Cham, C. M., Ko, K. & Niewold, T. B. Interferon regulatory factor 5 in the pathogenesis of systemic lupus erythematosus. Clin. Dev. Immunol. 2012, 780436 (2012).","journal-title":"Clin. Dev. Immunol."},{"key":"60445_CR55","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41586-024-07501-1","volume":"630","author":"CT Stankey","year":"2024","unstructured":"Stankey, C. T. et al. A disease-associated gene desert directs macrophage inflammation through ETS2. Nature 630, 447\u2013456 (2024).","journal-title":"Nature"},{"key":"60445_CR56","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1172\/JCI39481","volume":"120","author":"T Watanabe","year":"2010","unstructured":"Watanabe, T. et al. NOD1 contributes to mouse host defense against Helicobacter pylori via induction of type I IFN and activation of the ISGF3 signaling pathway. J. Clin. Invest 120, 1645\u20131662 (2010).","journal-title":"J. Clin. Invest"},{"key":"60445_CR57","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3389\/fphar.2019.00445","volume":"10","author":"R Huang","year":"2019","unstructured":"Huang, R. et al. The NCATS bioplanet - an integrated platform for exploring the universe of cellular signaling pathways for toxicology, systems biology, and chemical genomics. Front Pharm. 10, 445 (2019).","journal-title":"Front Pharm."},{"key":"60445_CR58","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M. et al. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res 51, D587\u2013d592 (2023).","journal-title":"Nucleic Acids Res"},{"key":"60445_CR59","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/978-1-0716-0301-7_7","volume":"2117","author":"CB Steen","year":"2020","unstructured":"Steen, C. B. et al. Profiling cell type abundance and expression in bulk tissues with CIBERSORTx. Methods Mol. Biol. 2117, 135\u2013157 (2020).","journal-title":"Methods Mol. Biol."},{"key":"60445_CR60","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/art.42476","volume":"75","author":"K Yi","year":"2023","unstructured":"Yi, K. et al. Analysis of single-cell transcriptome and surface protein expression in ankylosing spondylitis identifies OX40-positive and glucocorticoid-induced tumor necrosis factor receptor-positive pathogenic Th17 Cells. Arthritis Rheumatol. 75, 1176\u20131186 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"60445_CR61","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/ng.2007.17","volume":"39","author":"PR Burton","year":"2007","unstructured":"Burton, P. R. et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet. 39, 1329\u20131337 (2007).","journal-title":"Nat. Genet."},{"key":"60445_CR62","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1189\/jlb.2A0514-257RR","volume":"98","author":"Z Ortutay","year":"2015","unstructured":"Ortutay, Z. et al. Proprotein convertase FURIN regulates T cell receptor-induced transactivation. J. Leukoc. Biol. 98, 73\u201383 (2015).","journal-title":"J. Leukoc. Biol."},{"key":"60445_CR63","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41590-019-0316-2","volume":"20","author":"C Neumann","year":"2019","unstructured":"Neumann, C. et al. c-Maf-dependent Treg cell control of intestinal TH17 cells and IgA establishes host\u2013microbiota homeostasis. Nat. Immunol. 20, 471\u2013481 (2019).","journal-title":"Nat. Immunol."},{"key":"60445_CR64","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/j.immuni.2022.09.013","volume":"55","author":"JA Hall","year":"2022","unstructured":"Hall, J. A. et al. Transcription factor ROR\u03b1 enforces stability of the Th17 cell effector program by binding to a Rorc cis-regulatory element. Immunity 55, 2027\u20132043.e9 (2022).","journal-title":"Immunity"},{"key":"60445_CR65","doi-asserted-by":"publisher","first-page":"v22","DOI":"10.1093\/rheumatology\/kes115","volume":"51","author":"P Emery","year":"2012","unstructured":"Emery, P. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology 51, v22\u2013v30 (2012).","journal-title":"Rheumatology"},{"key":"60445_CR66","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1002\/art.24941","volume":"60","author":"J Askling","year":"2009","unstructured":"Askling, J. et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?. Arthritis Rheum. 60, 3180\u20133189 (2009).","journal-title":"Arthritis Rheum."},{"key":"60445_CR67","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1093\/rheumatology\/keae309","volume":"64","author":"S Gertel","year":"2024","unstructured":"Gertel, S. et al. Ex vivo cell-based assay for assessment of response to TNF inhibitors in patients with rheumatic diseases. Rheumatology 64, 2233\u20132241 (2024).","journal-title":"Rheumatology"},{"key":"60445_CR68","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.autrev.2008.12.002","volume":"8","author":"EY Lee","year":"2009","unstructured":"Lee, E. Y., Lee, Z. H. & Song, Y. W. CXCL10 and autoimmune diseases. Autoimmun. Rev. 8, 379\u2013383 (2009).","journal-title":"Autoimmun. Rev."},{"key":"60445_CR69","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1189\/jlb.5A0717-302","volume":"102","author":"Q Zhao","year":"2017","unstructured":"Zhao, Q. et al. A novel function of CXCL10 in mediating monocyte production of proinflammatory cytokines. J. Leukoc. Biol. 102, 1271\u20131280 (2017).","journal-title":"J. Leukoc. Biol."},{"key":"60445_CR70","doi-asserted-by":"publisher","first-page":"688753","DOI":"10.3389\/fimmu.2021.688753","volume":"12","author":"H Enocsson","year":"2021","unstructured":"Enocsson, H. et al. Comparison of surrogate markers of the type i interferon response and their ability to mirror disease activity in systemic lupus erythematosus. Front Immunol. 12, 688753 (2021).","journal-title":"Front Immunol."},{"key":"60445_CR71","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","volume":"359","author":"N Shakoor","year":"2002","unstructured":"Shakoor, N. et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359, 579\u2013580 (2002).","journal-title":"Lancet"},{"key":"60445_CR72","doi-asserted-by":"publisher","first-page":"R545","DOI":"10.1186\/ar1715","volume":"7","author":"M De Bandt","year":"2005","unstructured":"De Bandt, M. et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 7, R545\u2013R551 (2005).","journal-title":"Arthritis Res Ther."},{"key":"60445_CR73","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1093\/rheumatology\/kep270","volume":"48","author":"M Aringer","year":"2009","unstructured":"Aringer, M. et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatol. (Oxf.) 48, 1451\u20131454 (2009).","journal-title":"Rheumatol. (Oxf.)"},{"key":"60445_CR74","doi-asserted-by":"publisher","first-page":"635018","DOI":"10.3389\/fimmu.2021.635018","volume":"12","author":"Q Zhou","year":"2021","unstructured":"Zhou, Q. et al. SARS-CoV-2 infection induces psoriatic arthritis flares and enthesis resident plasmacytoid dendritic cell type-1 interferon inhibition by JAK antagonism offer novel spondyloarthritis pathogenesis insights. Front Immunol. 12, 635018 (2021).","journal-title":"Front Immunol."},{"key":"60445_CR75","doi-asserted-by":"publisher","first-page":"785","DOI":"10.4049\/jimmunol.1901358","volume":"206","author":"A Psarras","year":"2021","unstructured":"Psarras, A. et al. TNF-\u03b1 regulates human plasmacytoid dendritic cells by suppressing ifn-\u03b1 production and enhancing T cell activation. J. Immunol. 206, 785\u2013796 (2021).","journal-title":"J. Immunol."},{"key":"60445_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02466-4","volume":"9","author":"C Conrad","year":"2018","unstructured":"Conrad, C. et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat. Commun. 9, 25 (2018).","journal-title":"Nat. Commun."},{"key":"60445_CR77","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/intimm\/dxu102","volume":"27","author":"C Monaco","year":"2015","unstructured":"Monaco, C. et al. Anti-TNF therapy: past, present and future. Int Immunol. 27, 55\u201362 (2015).","journal-title":"Int Immunol."},{"key":"60445_CR78","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/ard-2023-223850","volume":"83","author":"M Bonelli","year":"2024","unstructured":"Bonelli, M. et al. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. Ann. Rheum. Dis. 83, 139\u2013160 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"60445_CR79","doi-asserted-by":"publisher","first-page":"e002280","DOI":"10.1136\/rmdopen-2022-002280","volume":"8","author":"D van der Heijde","year":"2022","unstructured":"van der Heijde, D. et al. Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension. RMD Open 8, e002280 (2022).","journal-title":"RMD Open"},{"key":"60445_CR80","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/acr2.11601","volume":"5","author":"A Deodhar","year":"2023","unstructured":"Deodhar, A. et al. Tofacitinib efficacy and safety in patients with ankylosing spondylitis by prior biologic disease-modifying antirheumatic drug use: a post hoc analysis. ACR Open Rheumatol. 5, 632\u2013643 (2023).","journal-title":"ACR Open Rheumatol."},{"key":"60445_CR81","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett, S. et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J. Rheumatol. 21, 2286\u20132291 (1994).","journal-title":"J. Rheumatol."},{"key":"60445_CR82","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park, W. et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann. Rheum. Dis. 72, 1605\u20131612 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"60445_CR83","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587.e29 (2021).","journal-title":"Cell"},{"key":"60445_CR84","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41586-020-2222-z","volume":"582","author":"K Wei","year":"2020","unstructured":"Wei, K. et al. Notch signalling drives synovial fibroblast identity and arthritis pathology. Nature 582, 259\u2013264 (2020).","journal-title":"Nature"},{"key":"60445_CR85","doi-asserted-by":"crossref","unstructured":"Choudhary, S. & Satija, R. Comparison and evaluation of statistical error models for scRNA-seq. Genome Biol. 23, 27 (2022).","DOI":"10.1186\/s13059-021-02584-9"},{"key":"60445_CR86","doi-asserted-by":"crossref","unstructured":"Van de Sande, B., et al. A scalable SCENIC workflow for single-cell gene regulatory network analysis. Nat. Protocols, 15, 2247\u20132276 (2020).","DOI":"10.1038\/s41596-020-0336-2"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60445-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60445-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60445-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:04:09Z","timestamp":1751371449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60445-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60445"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60445-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Eun Young Lee is a consultant for Samsung Bioepis and IMBiologics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5531"}}